Good result for GlaxoSmithKline Lupus treatment

2nd Nov 2009 07:35

GlaxoSmithKline has received a boost for Benlysta, its new treatment for systemic lupus erythematosus or Lupus, after the latest phase 3 trial showed a significant improvement in those patients given the drug.GlaxoSmithKline, and its partner Human Genome Sciences, said that Benlysta (belimumab) met its primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus and was generally well-tolerated."The results from this second pivotal Phase 3 trial reinforce our belief that belimumab could deliver a significant therapeutic option for patients with lupus who have had no new treatment in 50 years. We look forward to continuing our collaboration with HGS in order to bring this important medicine to patients," Carlo Russo, GlaxoSmithKline's Senior Vice President, Biopharm Development, said.Lupus, or SLE, is an autoimmune tissue disease that can affect any part of the body and results in the immune system attacking the body's own cells. There are approximately 5m sufferers worldwide, with the disease most prevalent in young people aged 15 to 45.